TCHBF Stock Chart & Stats
$242.88
$27.65(13.96%)
At close: 4:00 PM EDT
$242.88
$27.65(13.96%)
Day’s Range― - ―
52-Week Range$136.95 - $317.25
Previous CloseN/A
Volume1.00
Average Volume (3M)7.00
Market Cap
$3.82B
Enterprise Value$2.00B
Total Cash (Recent Filing)$224.63M
Total Debt (Recent Filing)$214.32M
Price to Earnings (P/E)―
Beta0.99
Next Earnings
Mar 16, 2027EPS Estimate
4.27Next Dividend Ex-DateN/A
Dividend Yield0.64%
Share Statistics
EPS (TTM)-9.16
Shares Outstanding12,825,883
10 Day Avg. Volume0
30 Day Avg. Volume7
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)1.41
Price to Sales (P/S)1.84
P/FCF Ratio15.85
Enterprise Value/Market Cap0.52
Enterprise Value/Revenue2.29
Enterprise Value/Gross Profit6.73
Enterprise Value/Ebitda20.35
Forecast
1Y Price Target
$273.55Price Target Upside12.63% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)7.75
Revenue Forecast (FY)$1.08B
Bulls Say, Bears Say
Bulls Say
Recurring Revenue ModelThe installed base supports repeat consumables, maintenance, software and service purchases after the initial instrument sale. This mix can make revenue less dependent on new capital-equipment orders and deepen customer relationships as laboratory workflows remain automated.
Conservative LeverageLow leverage provides financial flexibility while Tecan funds operations, transformation initiatives and customer-facing investment. A conservative capital structure can reduce refinancing pressure and help the company absorb earnings volatility without relying heavily on additional borrowing.
Operational Growth OutlookAbove-market local-currency growth, reiterated margin guidance and reaffirmed 2028 targets indicate that management sees a path toward improved scale and profitability. The outlook is supported by demand across biopharma, diagnostics and other automation applications.
Bears Say
Revenue And Earnings DeteriorationMulti-year revenue contraction and the swing to a substantial 2025 net loss indicate that recent operating momentum has not translated into durable reported earnings. This weakens internal funding capacity and raises the execution burden for the recovery plan.
Gross Margin PressureThe decline in gross margin shows that input costs, inventory effects and external pricing pressures are currently absorbing part of Tecan's revenue growth. Sustained compression would limit operating leverage and make the 2028 margin ambition more dependent on successful restructuring.
Weaker Cash ConversionLower operating cash flow alongside higher receivables and inventory indicates weaker cash conversion from current activity. If this persists, it could constrain funding for transformation and product investment even if adjusted profitability improves.
TCHBF FAQ
What was Tecan Group AG’s price range in the past 12 months?
Tecan Group AG lowest stock price was $136.95 and its highest was $317.25 in the past 12 months.
What is Tecan Group AG’s market cap?
Tecan Group AG’s market cap is $3.82B.
When is Tecan Group AG’s upcoming earnings report date?
Tecan Group AG’s upcoming earnings report date is Mar 16, 2027 which is in 144 days.
How were Tecan Group AG’s earnings last quarter?
Tecan Group AG released its earnings results on Aug 11, 2026. The company reported $3.159 earnings per share for the quarter, beating the consensus estimate of $3.027 by $0.133.
Is Tecan Group AG overvalued?
According to Wall Street analysts Tecan Group AG’s price is currently Undervalued.
Does Tecan Group AG pay dividends?
Tecan Group AG pays a Annually dividend of $1.927 which represents an annual dividend yield of 0.64%. See more information on Tecan Group AG dividends here
What is Tecan Group AG’s EPS estimate?
Tecan Group AG’s EPS estimate is 4.27.
How many shares outstanding does Tecan Group AG have?
Tecan Group AG has 12,825,883 shares outstanding.
What happened to Tecan Group AG’s price movement after its last earnings report?
Tecan Group AG reported an EPS of $3.159 in its last earnings report, beating expectations of $3.027. Following the earnings report the stock price went down -6.158%.
Which hedge fund is a major shareholder of Tecan Group AG?
Currently, no hedge funds are holding shares in TCHBF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Tecan Group AG
Tecan Group AG, established in 1980 and headquartered in Männedorf, Switzerland, specializes in providing cutting-edge laboratory instruments and holistic solutions. The company caters to a broad spectrum of clients, including pharmaceutical and biotechnology corporations, university research departments, and forensic and diagnostic laboratories. Its operations are structured into two principal segments: Life Sciences Business and Partnering Business. Tecan's extensive product portfolio features automated liquid handling systems, microplate readers and washers, various consumables, reagents for Next-Generation Sequencing (NGS), immunoassays, microbodies, and specialized software. Key proprietary solutions include Tecan Laberwax for automated workflows and Resolvex, an intelligent sample preparation system applicable across diverse fields such as genomics, synthetic biology, drug discovery, analytical chemistry, cell biology, protein science, applied markets, and ELISA. Additionally, Tecan develops and manufactures crucial components—like precision pumps, valves, robotic arms, and developer software—for other laboratory instrument producers serving life science research, diagnostics, and various industrial applications. Its advanced platform-based automation solutions include Synergence, Freedom EVO, and Fluent instruments. The company's global footprint spans Switzerland, other European nations, North America, Asia, and other international markets.
TCHBF Company Deck
TCHBF Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call painted an overall constructive picture: Tecan delivered above-market sales growth in local currencies, maintained a healthy book-to-bill and recorded a resilient adjusted EBITDA margin with underlying profitability improvement. Management confirmed multi-year targets and reported early, tangible benefits from the Rewired transformation alongside strategic AI and geographic initiatives. However, material challenges remain — gross margin compression (material inflation, FX and tariffs), weaker operating cash flow, supply-chain shipment delays (Cavro), upfront transformation and IT costs, and weakness in the Academia & Government end market. On balance, the positive operational momentum, validated guidance and strategic progress outweigh the near-term financial and operational headwinds, but the company must execute Rewired and Elevate while stabilizing cash conversion and margins.View all TCHBF earnings summariesTCHBF Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
$273.55
▲(12.63% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month
Ownership Overview
―
Insiders
7.15% Mutual Funds
<0.01% Other Institutional Investors
83.16% Public Companies and
Individual Investors











